< div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " >..."> < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " >..." /> < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " >..." />

New KEYTRUDA ® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression < /p > < p > KEYNOTE-001 Findings Show Responses Are Durable and Include Two Year Overall Survival Data for KEYTRUDA < /p > < p > < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data, including updated response rates, progression-free survival (PFS) and overall survival (OS) with KEYTRUDA < sup > ® < /sup > (pembrolizumab), the company ’s anti-PD-1 therapy, as a monotherapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 from two studies: KEYNOTE-010 and KEYNOTE-001. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressrel...
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO cancer Keytruda MSD Source Type: news